First Tracks Biotherapeutics, ANB033, celiac disease, CD122 antagonist, Phase 1b clinical trial, gluten challenge, mucosal damage, autoimmune disease, immunology

SAN DIEGO, California — October 11, 2026 First Tracks Biotherapeutics, Inc. announced that it will report top-line results from...